 ROCKVILLE, MD, Feb. 11, 2021 GLOBE NEWSWIRE -- MacroGenics, Inc. Nasdaq: MGNX, a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that a 10 million milestone has been achieved related to development progress of retifanlimab outside the U.S., under its exclusive global collaboration and license agreement with Incyte. Retifanlimab is an investigational anti-PD-1 monoclonal antibody designed by MacroGenics and licensed to Incyte as INCMGA0012. 